MedCity News October 25, 2024
Septerna’s lead program is in Phase 1 testing for hypoparathyroidism. The therapies available and in development for this rare disease are injectable, and Septerna aims to stand apart with an oral GPCR-targeting small molecule.
Septerna just entered the clinic, and its lack of human data makes it an outlier among the companies able to successfully go public this year in what is still a cautious biotech IPO market. What the young company does have is technology based on research from a Nobel laureate and a lead drug candidate that could offer a key advantage over other treatments for a rare, inherited disease. Now it has $288 million in IPO cash to support its pipeline.
Late Thursday, Septerna priced its offering...
Today's Sponsors
Today's Sponsor